Genmab A/S
F:GE9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Genmab A/S
F:GE9
|
DK |
|
C
|
Compagnie Financiere Richemont SA
XMUN:RITN
|
CH |
|
B
|
Bukit Asam (Persero) Tbk PT
XMUN:TBA
|
ID |
|
Xiaomi Corp
OTC:XIACF
|
CN |
|
G
|
Globant SA
LSE:0RIX
|
LU |
|
L'Oreal SA
PAR:OR
|
FR |
|
V
|
Volkswagen AG
F:VOW
|
DE |
|
BRP Inc
TSX:DOO
|
CA |
|
Washington H. Soul Pattinson and Company Ltd
ASX:SOL
|
AU |
Wall St Price Targets
GE9 Price Targets Summary
Genmab A/S
According to Wall Street analysts, the average 1-year price target for GE9 is 339.11 EUR with a low forecast of 188.04 EUR and a high forecast of 409.12 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is GE9's stock price target?
Price Target
339.11
EUR
According to Wall Street analysts, the average 1-year price target for GE9 is 339.11 EUR with a low forecast of 188.04 EUR and a high forecast of 409.12 EUR.
What is the Revenue forecast for Genmab A/S?
Projected CAGR
10%
Over the last 13 years, the compound annual growth rate for Revenue has been 34%. The projected CAGR for the next 8 years is 10%.
What is the Gross Profit forecast for Genmab A/S?
Projected CAGR
7%
The compound annual growth rate for Gross Profit over the next 8 years is 7%.
What is the Operating Income forecast for Genmab A/S?
Projected CAGR
10%
The compound annual growth rate for Operating Income over the next 8 years is 10%.
What is the Pre-Tax Income forecast for Genmab A/S?
Projected CAGR
20%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 20%.
What is the Net Income forecast for Genmab A/S?
Projected CAGR
12%
The compound annual growth rate for Net Income over the next 8 years is 12%.